Trial Profile

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Respiratory Combination Vaccine Candidates in Older Adults

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 26 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BNT 161 (Primary) ; Respiratory syncytial virus vaccine Pfizer (Primary)
Indications Influenza virus infections; Respiratory syncytial virus infections
Focus Adverse reactions; Pharmacodynamics
Sponsors Pfizer

Most Recent Events

10 Oct 2023 Status changed from active, no longer recruiting to completed.
15 Sep 2023 Planned End Date changed from 16 Sep 2023 to 28 Sep 2023.
15 Sep 2023 Planned primary completion date changed from 16 Sep 2023 to 28 Sep 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com